Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease. Issue 1 (10th February 2022)

• Record Type: Journal Article
• Authors: Alayo, Quazim A; Fenster, Marc; Altayar, Osama; Glassner, Kerri L; Llano, Ernesto; Clark-Snustad, Kindra; Patel, Anish; Kwapisz, Lukasz; Yarur, Andres J; Cohen, Benjamin L; Ciorba, Matthew A; Thomas, Deborah; Lee, Scott D; Loftus, Edward V; Fudman, David I; Abraham, Bincy P; Colombel, Jean-Frederic; Deepak, Parakkal
• Is Part Of: Crohn's & colitis 360. Volume 4:Issue 1(2022)
• Publication Date: 2022-02-10
• Subjects: inflammatory bowel diseases -- biologics -- ulcerative colitis -- Crohn's disease -- meta-analysis; Crohn's disease -- Periodicals; Colitis -- Periodicals; 616.344
• DOI: 10.1093/crocol/otac002
• Languages: English
• ISSNs: 2631-827X

Abstract

Abstract: Background: Combining biologics and small molecules could potentially overcome the plateau of drug efficacy in inflammatory bowel disease (IBD). We conducted a systematic review and meta-analysis to assess the safety and effectiveness of dual biologic therapy (DBT), or small molecule combined with a biologic therapy (SBT) in IBD patients. Methods: We searched MEDLINE, EMBASE, Scopus, Web of Science, Cochrane Database of Systematic Reviews, and Clinical trials.gov until November 3, 2020, including studies with 2 or more IBD patients on DBT or SBT. Main outcome was safety assessed as pooled rates of adverse events (AEs) and serious AEs (SAEs) for each combination. Effectiveness was reported as pooled rates of clinical, endoscopic, and/or radiographic response and remission. The certainty of evidence was rated according to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) framework. Results: Of the 3688 publications identified, 13 studies (1 clinical trial, 12 observational studies) involving 266 patients on 7 different combinations were included. Median number of prior biologics ranged from 0 to 4, and median duration of follow-up was 16–68 weeks. Most common DBT and SBT were vedolizumab (VDZ) with anti-tumor necrosis factor (aTNF, n = 56) or tofacitinib (Tofa, n = 57), respectively. Pooled rates of SAE for these were 9.6% (95% confidence interval [CI], 1.5–21.4) for VDZ-aTNF and 1.0% (95% CI, 0.0–7.6) for Tofa-VDZ. The overall certainty of evidence was very low due to the observational nature of the studies, and very serious imprecision and inconsistency. Conclusions: DBT or SBT appears to be generally safe and may be effective in IBD patients, but the evidence is very uncertain. Lay Summary: Our study suggests that a combination of 2 biologics or a biologic with a small molecule drug appears safe, with no new adverse event signal. These combinations may be potentially effective as a therapeutic option in treatment refractory inflammatory bowel disease patients, but the evidence is very uncertain.